首页> 美国卫生研究院文献>Epidemiology and Psychiatric Sciences >Trends in the access to and the use of antipsychotic medications and psychotropic co-treatments in Asian patients with schizophrenia
【2h】

Trends in the access to and the use of antipsychotic medications and psychotropic co-treatments in Asian patients with schizophrenia

机译:亚洲精神分裂症患者获得和使用抗精神病药物和精神药物联合疗法的趋势

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

To date, antipsychotics remain the mainstay of treatment for schizophrenia and related disorders although other psychotropic medications and non-pharmaceutical interventions have been used adjunctively in some patients and settings. Regular surveys on access to and prescription patterns of psychotropic medications in clinical practice are an important and efficient way of examining the use and time trends of treatments in a given population and region. Unlike developed Western countries, Asian countries have not fully undergone deinstitutionalisation of the severely and chronically mentally ill, and community-based mental health services are still under-developed. As a result, a large number of psychiatric patients still receive treatments in psychiatric hospitals. Moreover, there have been very limited studies examining access to and prescription patterns of psychotropic medications for schizophrenia patients in Asian countries. In this paper, we focus on the only international project on the use of psychotropic medications in schizophrenia patients summarising its major findings. Most of the first- and second-generation antipsychotics (FGAs and SGAs) are available in Asian countries, but the access to psychotropic medications is largely affected by socio-cultural and historical contexts, health insurance schemes, health care policy, medication cost and consumers’ preference across different countries/territories. Overall, the proportional use of FGAs, high dose antipsychotic treatment and antipsychotic polypharmacy have decreased, while the use of SGAs and antidepressants have increased and the utilisation of benzodiazepines and mood stabilisers has remained relatively stable over time. However, within these general trends, there is great inter-country variation regarding the psychotropic prescribing patterns and trends in Asian schizophrenia patients that also seems to differ from data in many Western countries.
机译:迄今为止,抗精神病药仍然是精神分裂症和相关疾病的主要治疗手段,尽管在某些患者和环境中辅助使用了其他精神药物和非药物干预措施。在临床实践中,定期就精神药物的获取和处方方式进行调查是检查给定人群和地区中治疗方法的使用和时间趋势的重要而有效的方法。与发达的西方国家不同,亚洲国家还没有对重度和慢性精神病患者完全实行非机构化,而基于社区的精神卫生服务仍然不发达。结果,许多精神病患者仍然在精神病医院接受治疗。此外,在亚洲国家,研究精神分裂症患者使用精神药物的方式和处方方式的研究非常有限。在本文中,我们集中于精神分裂症患者使用精神药物的唯一国际项目,总结其主要发现。大多数第一代和第二代抗精神病药(FGA和SGA)可在亚洲国家获得,但是获得精神药物的机会在很大程度上受到社会文化和历史背景,健康保险计划,医疗政策,药物成本和消费者的影响'跨不同国家/地区的偏好。总体而言,FGA,高剂量抗精神病药和抗精神病药房的使用比例有所下降,而SGA和抗抑郁药的使用量却有所增加,并且苯二氮卓类和情绪稳定剂的使用率一直保持相对稳定。但是,在这些总体趋势中,亚洲精神分裂症患者的精神处方模式和趋势在国家间存在很大差异,这似乎也与许多西方国家的数据有所不同。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号